0000000000643823

AUTHOR

Eleonora Riccio

showing 5 related works from this author

A pilot study of circulating microRNAs as potential biomarkers of Fabry disease

2018

Patients suffering from Fabry disease (FD), a lysosomal storage disorder, show a broad range of symptoms and the diagnosis followed by the therapeutic decision remains a great challenge. The biomarkers available today have not proven to be useful for predicting the evolution of the disease and for assessing response to therapy in many patients. Here, we used high-throughput microRNA profiling methodology to identify a specific circulating microRNA profile in FD patients. We discovered a pattern of 10 microRNAs able to identify FD patients when compared to healthy controls. Notably, two of these: the miR199a-5p and the miR-126-3p are able to discriminate FDs from the control subjects with le…

0301 basic medicineOncologymedicine.medical_specialtyDisease030204 cardiovascular system & hematologyLeft ventricular hypertrophy03 medical and health sciences0302 clinical medicineSettore BIO/13 - Biologia ApplicataInternal medicinemedicinePathologyEndothelial dysfunctionPathologicalFabry diseasebusiness.industryMicroRNAEnzyme replacement therapyBiomarkermedicine.diseaseFabry diseaseBiomarker; ERT; Fabry disease; LVH; MicroRNA; Pathology; OncologyCirculating MicroRNALVH030104 developmental biologyOncologyBiomarker (medicine)ERTbusiness
researchProduct

Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis.

2017

PURPOSE: Multiple sclerosis (MS) has been proposed as a possible differential diagnosis for Fabry disease (FD). The aim of this work was to evaluate the involvement of corpus callosum (CC) on MR images and its possible role as a radiological sign to differentiate between FD and MS. METHODS: In this multicentric study, we retrospectively evaluated the presence of white matter lesions (WMLs) on the FLAIR images of 104 patients with FD and 117 patients with MS. The incidence of CC-WML was assessed in the two groups and also in a subgroup of 37 FD patients showing neurological symptoms. RESULTS: WMLs were detected in 50 of 104 FD patients (48.1%) and in all MS patients. However, a lesion in the…

AdultMalemedicine.medical_specialtyPathologyNeurologySettore MED/09 - Medicina InternaAdolescentCorpus callosumFluid-attenuated inversion recoveryCorpus callosumCorpus callosum; Fabry disease; MRI; Multiple sclerosis030218 nuclear medicine & medical imagingDiagnosis DifferentialMultiple sclerosis03 medical and health sciences0302 clinical medicinemedicineHumansRadiology Nuclear Medicine and imagingAgedRetrospective StudiesNeuroradiologyFabry diseasebusiness.industryMultiple sclerosisMiddle Agedmedicine.diseaseMagnetic Resonance ImagingFabry diseaseHyperintensityCorpus callosum; Fabry disease; MRI; Multiple sclerosis.FemaleNeurology (clinical)RadiologyDifferential diagnosisCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryMRI
researchProduct

Molecular and clinical studies in five index cases with novel mutations in the GLA gene

2016

Fabry disease is a metabolic and lysosomal storage disorder caused by the functional defect of the α-galactosidase A enzyme; this defect is due to mutations in the GLA gene, that is composed of seven exons and is located on the long arm of the X-chromosome (Xq21–22). The enzymatic deficit is responsible for the accumulation of glycosphingolipids in lysosomes of different cellular types, mainly in those ones of vascular endothelium. It consequently causes a cellular and microvascular dysfunction. In this paper, we described five novel mutations in the GLA gene, related to absent enzymatic activity and typical manifestations of Fabry disease. We identified three mutations (c.846_847delTC, p.E…

0301 basic medicineAdultMalep.R227Pnovel moutationAdolescentc.639 + 5G > TMutation MissenseBiologyLeft ventricular hypertrophy03 medical and health sciencesExonYoung Adult0302 clinical medicineSettore BIO/13 - Biologia ApplicataGeneticsmedicinefabry; novel moutationMissense mutationAlpha-galactosidase AHumansPoint MutationCornea verticillataGenetic Predisposition to DiseaseChildfabryGLA genec.846_847delTCGeneticsAlpha-galactosidasePoint mutationFabry disease; Alpha-galactosidase A; c.846_847delTC; p.E341X; p.C382X; p.R227P; c.639 + 5G > Tp.E341XGeneral MedicineMiddle Agedmedicine.diseaseMolecular biologyFabry diseaseStop codon030104 developmental biologyp.C382Xalpha-Galactosidasebiology.proteinFabry DiseaseFemalemedicine.symptom030217 neurology & neurosurgery
researchProduct

Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?

2018

Anderson-Fabry disease (FD) is a rare, progressive, multisystem storage disorder caused by the partial or total deficit of the lysosomal enzyme &alpha

0301 basic medicineProbandMaleDiseasemedicine.disease_causeSphingolipidCatalysilcsh:Chemistry0302 clinical medicineGla geneFabry disease; GLA gene; LysoGb3MedicineChildlcsh:QH301-705.5Spectroscopychemistry.chemical_classificationGeneticsAlleleAged 80 and overMutationComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineMiddle AgedPhenotype3. Good healthComputer Science ApplicationsPhenotypeChild PreschoolFemaleHumanAdultAdolescentGenotypeGlycolipidCatalysisArticleInorganic Chemistry03 medical and health sciencesYoung Adultotorhinolaryngologic diseasesHumansPhysical and Theoretical ChemistryMolecular BiologyGeneGLA geneAllelesAgedFabry diseaseSphingolipidsbusiness.industryOrganic ChemistryInfant NewbornLysoGb3InfantBiomarkerFabry disease; gla gene; lysogb3; adolescent; adult; aged; aged 80 and over; alleles; amino acid substitution; biomarkers; child; child preschool; fabry disease; female; genotype; glycolipids; humans; infant; infant newborn; male; middle aged; phenotype; sphingolipids; young adult; alpha-galactosidase; mutationmedicine.diseaseFabry disease030104 developmental biologyEnzymechemistrylcsh:Biology (General)lcsh:QD1-999Amino Acid Substitutionalpha-GalactosidaseMutationGlycolipidsbusiness030217 neurology & neurosurgeryBiomarkersInternational Journal of Molecular Sciences
researchProduct

CKD NUTRITION, INFLAMMATION AND OXIDATIVE STRESS

2014

Introduction and Aims: Serum p-cresyl sulfate associates with cardiovascular disease in patients at different stages of chronic kidney disease. p-Cresyl sulfate concentrations are determined by intestinal uptake of p-cresol, human metabolism to p-cresyl sulfate and renal clearance. Whether intestinal uptake of p-cresol itself is associated with cardiovascular disease in patients with renal disease has not been studied to date. Methods: We performed a prospective study in patients with chronic kidney disease stage 1-5 (clinicaltrials.gov NCT00441623). Intestinal uptake of p-cresol, under steady state conditions, was estimated from 24h urinary excretion of p-cresyl sulfate. Primary endpoint w…

Transplantationmedicine.medical_specialtyFramingham Risk ScoreCardiovascular Historybusiness.industryHazard ratioRenal functionmedicine.diseaseGastroenterologyEndocrinologyNephrologyDiabetes mellitusInternal medicinemedicineMyocardial infarctionProspective cohort studybusinessKidney diseaseNephrology Dialysis Transplantation
researchProduct